Vidipha (VDP) Rights Offering: 10M Shares at 10,000 VND to Fund Cephalosporin Line
This Aveluro analysis covers VDP on HOSE in the Health Care sector. The classified event type is capital raise, with neutral sentiment and a deterministic market-impact score of 4.8/10. Source coverage came from CafeF - Thị trường chứng khoán, classified as a primary/top-tier source.
Key Facts
Caveat: Not investment advice. · How Aveluro computed this: Aveluro combines extracted event facts, source credibility, ticker context, and market data. Scores are deterministic research signals, not recommendations.
Overview
Vidipha (VDP, HOSE) has announced a rights offering of nearly 10 million shares to existing shareholders at 10,000 VND per share, aiming to raise over 99.3 billion VND. The proceeds will fund a new Cephalosporin injection production line designed to meet EU-GMP standards, with total investment of 127.8 billion VND. The offering will increase charter capital from 220.8 billion VND to 320.2 billion VND.
Key Facts
- Record date for rights entitlement: July 24, 2026.
- Rights ratio: 100:45 (100 existing shares entitle purchase of 45 new shares).
- Issue price: 10,000 VND per share, a 79.7% discount to the recent close of 49,200 VND (July 15, 2026).
- Total proceeds: 99.3 billion VND (approximately USD 3.97 million).
- Use of funds: 2 billion VND for factory renovation (6,500 m²) and 97.2 billion VND for machinery and equipment.
- Total project cost: 127.8 billion VND; any shortfall will be covered by commercial bank loans.
- Production line capacity: 10 million vials per year, expected to begin operations in January 2028.
- Major shareholders: DSC (4.36 million shares), DVN (3.1 million shares), and individuals including Chair Kieu Huu (1.65 million shares).
What Happened
Vidipha announced on July 19, 2026, that its board has set a record date of July 24 for a rights offering to existing shareholders. The company will issue 9.94 million shares at 10,000 VND/share, with the subscription period running from August 5 to August 26, 2026. Rights are transferable once during the trading period from August 5 to August 20.
The funds will be used exclusively to build a Cephalosporin injection production line targeting EU-GMP certification. The project, with a total budget of 127.8 billion VND, includes renovation of a 6,500 m² facility and procurement of advanced manufacturing equipment. If the rights offering does not raise sufficient capital, the board plans to secure additional financing from commercial banks.
Market Context
VDP shares closed at 49,200 VND on July 15, 2026, on HOSE, representing a significant premium to the rights issue price. The stock has been trading in a range of 40,000-55,000 VND over the past six months. The rights offering is priced at a deep discount, which may attract strong participation from existing shareholders. The pharmaceutical sector in Vietnam has seen increased investment in high-quality manufacturing as regulatory standards tighten.
Strategic Significance
This capital raise positions Vidipha to upgrade its manufacturing capabilities to EU-GMP standards, a key differentiator in the Vietnamese pharmaceutical market. The Cephalosporin injection line targets a high-demand antibiotic segment, potentially expanding the company’s product portfolio and market share. The participation of major shareholders like DSC and DVN signals confidence in the project’s long-term value. Successful execution could enhance Vidipha’s competitiveness and margin profile.
What to Watch
- Subscription results and final capital raised by August 26, 2026.
- Progress of factory renovation and equipment procurement through 2027.
- Regulatory approvals for EU-GMP certification of the new line.
- Impact on VDP’s financials: expected revenue and profit contributions from the new line starting 2028.
- Share price reaction post-rights and potential dilution effects.